SOURCES SOUGHT
A -- Animal Models for the Prevention and Treatment of Hepatitis B and C
- Notice Date
- 7/2/2004
- Notice Type
- Sources Sought
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institutes of Allergy and Infectious Diseases, Contract Management Program 6700 B Rockledge Room 3214 MSC7612, Bethesda, MD, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- SS-NIH-NIAID-DMID-05-12
- Response Due
- 7/16/2004
- Archive Date
- 7/31/2004
- Point of Contact
- Yvette Brown, Contract Specialist, Phone 301-451-3686, Fax 301-496-0972, - Paul McFarlane, Senior Contracting Officer, Phone 301-496-0349, Fax 301-402-0972,
- E-Mail Address
-
YBrown@niaid.nih.gov, pm24v@nih.gov
- Description
- The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) seeks small characterized animal models for evaluating therapeutics against chronic infections and diseases caused by either hepatitis B or hepatitis C. The Preclinical Research Contracts Branch (PRCB) of the Contract Management Program (CMP) of the Division of Extramural Activities (DEA), NIAID is seeking capability statements from small business organizations with the technical expertise and facilities to support small mammalian animal models (e.g., mice, rats, small primates such as tamarins, tupaias, or marmosets, etc.) of HBV or HCV infection and disease, to test and apprise new drug candidates that may reduce or eliminate viral replication or prevent progression of liver disease. Results from testing a therapeutic in the animal model should predict human responses. Important considerations for selecting a model include the guaranteed provision of ample numbers of animals, and the availability of well-documented tools and assays for analysis of outcomes. As dose requirements are based usually on body weight, lighter is better. Endangered mammals or mammals over 5 kilograms are excluded. Additionally, HCV models are sought for testing protective vaccine candidates. The ideal small model is one infected with the human hepatitis virus and that subsequently expresses human-like symptoms and outcomes. To date, infections by HBV or HCV, complete with their associated disease progressions, are unique to humans. As evidenced by the success of the woodchuck model for HBV, surrogate infection models such as the marmoset or tamarin infected with the related flavivirus GBV-B are plausible contenders for HCV. Offerors may propose, however, any small mammalian animal model, including genetically altered or transplant models, which represents aspects of the human infection or viral hepatitis disease process, and also mimics the human response to licensed therapies. The Government anticipates multiple awards. It is anticipated that the duration of the contracts will be a maximum of five (5) years; however, the length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. Interested Small Business organizations should submit two (2) copies of their capability statement addressing the areas cited above. No submission shall exceed a maximum of 25 1-sided pages in a 12-point font. No collect calls will be accepted and no facsimile transmissions will be accepted. THIS IS NOT A REQUEST FOR PROPOSALS AND DOES NOT COMMIT THE GOVERNMENT TO ISSUE A SOLICITATION OR TO AWARD A CONTRACT NOW OR IN THE FUTURE. NO SOLICITATION IS AVAILABLE AT THIS TIME. THE NAICS CODE IS 54171 WITH A SIZE STANDARD OF 500 EMPLOYEES OR FEWER. See contact information above.
- Place of Performance
- Address: To Be Determined
- Zip Code: TBD
- Country: TBD
- Zip Code: TBD
- Record
- SN00614628-W 20040704/040702211730 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |